Our response to COVID-19

We're supporting people to maintain their wellbeing and manage isolation.

Digitally created image of a double helix

Genetic Repositories Australia (GRA)

FACILITY INFORMATION

In accordance with NHMRC Enabling Grant requirements GRA has established 3 committees:

  • Management Committee
  • Scientific Advisory Committee
  • Independent Appeals Committee

The Management Committee (MC) operates under defined terms of reference and provides management and oversight of the day-to-day management of the GRA facility. The MC role is to ensure that appropriate ethical standards are met, ensuring open access to all researchers, and overseeing the resolution of any disputes consistent with NHMRC Enabling Facility Access Policy.

  • The GRA MC comprises the four Chief Investigators and the Facility Manager.
  • Professor Peter Schofield BScAgr, PhD, DSc
  • Executive Director & CEO, Neuroscience Research Australia
  • Assoc Prof Juleen Cavanaugh BSc, MS, PhD
  • Senior Lecturer, Australian National University
  • Dr Susan Forrest BSc (Hons), D Phil, BA Business
  • Director, Australian Genome Research Facility Ltd
  • Professor John Hopper BA, MSc, PhD
  • NHMRC Senior Principal Research Fellow, The University of Melbourne
  • Steve Turner BAppSc, BSc (Hons), MSc, Grad Cert Man
  • Facility Manager, Genetic Repositories Australia.

A Scientific Advisory Committee (SAC) which consists of nine members. The SAC membership reflects a skills-based committee, with an appropriate mix of expertise to allow the SAC to provide advice in all areas of operations of the GRA facility. GRA’s SAC provides strategic advice and reviews progress towards establishing and operating GRA as an NHMRC Enabling Facility, including advice on governance, management and operations. The SAC is comprised of a majority of external appointments & includes all members from the GRA MC and the Facility Manager (Ex Officio).

External SAC members are listed below:

  • Professor Graham MacDonald, Formerly External Licensing Coordinator, Merck Sharp & Dohme (Australia)
  • Professor Don Chalmers, Faculty of Law, University of Tasmania
  • Theo Magoulas, Assistant University Solicitor, University of Technology Legal Services
  • Professor Phil Mitchell, Head School of Psychiatry, University of NSW
  • Dr Bruce Ross, Health Solutions Executive, Health Solutions Group Microsoft Australia.

An Independent Appeals Committee (IAC) of ’eminent persons’ who are independent of GRA and represent a range of consumer, scientific and social scientific disciplines. The IAC has been established to resolve any dispute concerning access to or operations of the facility and comprises individuals outside both Management and the SAC. The IAC comprises the following members:

  • Professor Ron Trent, Professor of Medicine at University of Sydney and Royal Prince Alfred Hospital
  • Peter Kemp, Founder of Kemp Strang Lawyers
  • A Consumer or Community Representative, (Position currently vacant)
See what’s going on at NeuRA

FEEL THE BUZZ IN THE AIR? US TOO.

What is the analgesic effect of EEG neurofeedback for people with chronic pain? A systematic review

Researchers: A/Prof Sylvia Gustin, Dr Negin Hesam-Shariati, Dr Wei-Ju Chang, A/Prof James McAuley, Dr Andrew Booth, A/Prof Toby Newton-John, Prof Chin-Teng Lin, A/Prof Zina Trost Chronic pain is a global health problem, affecting around one in five individuals in the general population. The understanding of the key role of functional brain alterations in the generation of chronic pain has led researchers to focus on pain treatments that target brain activity. Electroencephalographic (EEG) neurofeedback attempts to modulate the power of maladaptive EEG frequency powers to decrease chronic pain. Although several studies provide promising evidence, the effect of EEG neurofeedback on chronic pain is uncertain. This systematic review aims to synthesise the evidence from randomised controlled trials (RCTs) to evaluate the analgesic effect of EEG neurofeedback. The search strategy will be performed on five electronic databases (Cochrane Central, MEDLINE, Embase, PsycInfo, and CINAHL) for published studies and on clinical trial registries for completed unpublished studies. We will include studies that used EEG neurofeedback as an intervention for people with chronic pain. Risk of bias tools will be used to assess methodological quality of the included studies. RCTs will be included if they have compared EEG neurofeedback with any other intervention or placebo control. The data from RCTs will be aggregated to perform a meta-analysis for quantitative synthesis. In addition, non-randomised studies will be included for a narrative synthesis. The data from non-randomised studies will be extracted and summarised in a descriptive table. The primary outcome measure is pain intensity assessed by self-report scales. Secondary outcome measures include depressive symptoms, anxiety symptoms, and sleep quality measured by self-reported questionnaires. Further, we will investigate the non-randomised studies for additional outcomes addressing safety, feasibility, and resting-state EEG analysis.
PROJECT